Department of Cardiology, University of Health Sciences, Koşuyolu Heart Training and Research Hospital, İstanbul, Turkey.
Department of Cardiology, Faculty of Medicine, Medipol University, İstanbul, Turkey.
Anatol J Cardiol. 2022 Dec;26(12):902-913. doi: 10.5152/AnatolJCardiol.2022.1762.
Although pregnancy in women with pulmonary arterial hypertension has been considered a high-risk condition, current data regarding pregnancy with pulmonary arterial hypertension are scarce. In this study, we aimed to evaluate our single-center data on maternal and fetal outcomes in pregnant women with PAH and review currently available risk-based management strategies.
Our single-center study group comprised 35 women who became pregnant after the diagnosis of pulmonary arterial hypertension or in whom pulmonary arterial hypertension was diagnosed within early post-partum period. Clinical, laboratory, echocardiographic, and hemodynamic characteristics of pregnant and non-pregnant productive women with pulmonary arterial hypertension were compared, and similar comparison was also repeated for survivors and non-survivors in pregnant patient group.
Pregnancy was noted in 15% of the 228 females with pulmonary arterial hypertension who were of hormonally productive ages, generally well-tolerated until delivery. Elective abortion and pre-term delivery were documented in 1 (2.8%) and 12 (35.3%) pregnant women, respectively. Switching to sildenafil was the standard medication during pregnancy. Cesarian section was the preferred method of delivery in all pregnant women with pulmonary arterial hypertension and was performed without any complication. Clinic deteoriation within the first week of delivery was observed in 5 (41.6%) patients. Maternal mortality was noted in 13 (37.1%) patients and was documented to cumulate within the first month of delivery. However, any sign predicting post-partum clinical deterioration was not found. No fetal mortality was observed.
Despite the development of advanced therapies, pregnancy in pulmonary arterial hypertension still carries a high mortality risk and requires multi-disciplinary expert center care with more proactive management strategies.
尽管妊娠合并肺动脉高压被认为是一种高危情况,但目前关于肺动脉高压合并妊娠的数据仍然有限。在本研究中,我们旨在评估我们单中心关于肺动脉高压孕妇母婴结局的数据,并回顾目前可用的基于风险的管理策略。
我们的单中心研究组包括 35 名在诊断为肺动脉高压后怀孕或在产后早期诊断为肺动脉高压的女性。比较了妊娠和非妊娠有肺动脉高压的女性的临床、实验室、超声心动图和血流动力学特征,并对妊娠患者组的幸存者和非幸存者进行了类似的比较。
在 228 名有肺动脉高压的育龄女性中,有 15%怀孕,一般能耐受至分娩。1 例(2.8%)孕妇行选择性流产,12 例(35.3%)孕妇早产。怀孕期间标准药物治疗为西地那非。所有肺动脉高压孕妇均行剖宫产,无任何并发症。5 例(41.6%)孕妇在分娩后第一周内出现临床恶化。13 例(37.1%)孕妇死亡,均发生在分娩后第一个月内。然而,没有发现任何预测产后临床恶化的迹象。未观察到胎儿死亡。
尽管有了先进的治疗方法,妊娠合并肺动脉高压仍然存在高死亡率风险,需要多学科专家中心的护理,并采取更积极的管理策略。